|View printer-friendly version|
|October 10, 2001 11:39 a.m.|
|Teva Announces that Health Canada Has Approved Enhanced Labeling for Copaxone®|
Jerusalem, Israel, October 10, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Health Canada has approved enhanced labeling for its multiple sclerosis drug COPAXONE® (glatiramer acetate for injection). The new label reflects the positive result of a large multicenter, double-blind, placebo-controlled study that showed a significant reduction of MRI gadolinium-enhancing lesions (new active lesions) in patients treated with COPAXONE®. Physicians increasingly use MRI for their diagnosis and treatment of MS.